SCHEMBL20123071

SCHEMBL20123071

COc1ccc(-c2cc(Cl)cc3c4ccncc4n(C4CC4)c23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
GCGR P47871 1/20 0.39
MAPK14 Q16539 1/20 0.39
PIK3CD O00329 1/20 0.37
PRKDC P78527 1/20 0.37
ALDH1A1 P00352 3/20 0.36
CYP1A2 P05177 3/20 0.36
CASP1 P29466 3/20 0.36
CASP7 P55210 3/20 0.36
HSD17B10 Q99714 3/20 0.36
USP2 O75604 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 2/20 0.36
RPS6KA3 P51812 1/20 0.36
HASPIN Q8TF76 1/20 0.36
QPCT Q16769 1/20 0.36
QPCTL Q9NXS2 1/20 0.36
HIF1A Q16665 2/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664146 1.00 CYP11B1 (0.41) CYP11B1CYP11B2GCGRMAPK14PIK3CD
SCHEMBL20122793 0.81 HASPIN (0.44) CYP11B1CYP11B2GCGRMAPK14PIK3CD
SCHEMBL30664344 0.81 HASPIN (0.44) CYP11B1CYP11B2GCGRMAPK14PIK3CD
SCHEMBL30664129 0.78 DYRK1A (0.47) CYP11B1CYP11B2GCGRMAPK14PIK3CD
SCHEMBL20122845 0.78 DYRK1A (0.47) CYP11B1CYP11B2GCGRMAPK14PIK3CD
SCHEMBL20122738 0.75 DYRK1A (0.49) CYP11B1CYP11B2GCGRMAPK14PIK3CD
SCHEMBL12464506 0.74 MAOA (0.49) CYP11B1CYP11B2ALDH1A1CYP1A2HSD17B10
SCHEMBL20122885 0.70 KCNH2 (0.49) KCNH2DYRK1A
SCHEMBL30664200 0.70 KCNH2 (0.49) KCNH2DYRK1A
SCHEMBL20122886 0.70 DYRK1A (0.46) MAPK14KCNH2DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 CYP11B1 825/4885CYP11B2 1286/4885GCGR 1341/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 CYP11B1 825/4885CYP11B2 1286/4885GCGR 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.